Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Kairos Pharma (KAPA) EBT Margin (2024 - 2025)

Kairos Pharma's EBT Margin history spans 2 years, with the latest figure at 2.84% for Q2 2025.

  • For Q2 2025, EBT Margin fell 195284.0% year-over-year to 2.84%; the TTM value through Jun 2025 reached 3.38%, changed N/A, while the annual FY2025 figure was 10.89%, 852.0% down from the prior year.
  • EBT Margin reached 2.84% in Q2 2025 per KAPA's latest filing, down from 2.52% in the prior quarter.
  • In the past five years, EBT Margin ranged from a high of 1950.0% in Q2 2024 to a low of 2.89% in Q4 2024.